Drug company investors set to vote on executive pay, drug prices

A handful of drug makers have lost their battle with investors who had submitted proposals seeking more information on the potential link between executive compensation packages and rising drug prices.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.